US12251365 — Pharmaceutical formulations for subcutaneous administration
Method of Use · Assigned to AbbVie Deutschland GmbH and Co KG · Expires 2040-06-10 · 14y remaining
What this patent protects
This patent protects a method of treating Parkinson's disease and associated conditions by subcutaneously administering a composition of levodopa 4â²-monophosphate and carbidopa 4â²-monophosphate in a 20:1 weight ratio.
USPTO Abstract
The present disclosure relates to compositions of levodopa 4â²-monophosphate and carbidopa 4â²-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.
Drugs covered by this patent
- foscarbidopa (FOSCARBIDOPA) · AbbVie GK
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4030 |
— | foscarbidopa |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.